Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Accumulated Expenses (2018 - 2025)

Immucell (ICCC) has disclosed Accumulated Expenses for 14 consecutive years, with $977466.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 14.43% year-over-year to $977466.0, compared with a TTM value of $977466.0 through Sep 2025, down 14.43%, and an annual FY2024 reading of $1.2 million, up 26.8% over the prior year.
  • Accumulated Expenses was $977466.0 for Q3 2025 at Immucell, down from $1.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.3 million in Q2 2024 and bottomed at $222379.0 in Q1 2022.
  • Average Accumulated Expenses over 5 years is $825959.4, with a median of $879073.0 recorded in 2024.
  • The sharpest move saw Accumulated Expenses dropped 23.61% in 2022, then skyrocketed 237.22% in 2023.
  • Year by year, Accumulated Expenses stood at $585939.0 in 2021, then skyrocketed by 64.96% to $966553.0 in 2022, then fell by 2.44% to $942999.0 in 2023, then grew by 26.8% to $1.2 million in 2024, then dropped by 18.25% to $977466.0 in 2025.
  • Business Quant data shows Accumulated Expenses for ICCC at $977466.0 in Q3 2025, $1.1 million in Q2 2025, and $782390.0 in Q1 2025.